Medication info

Duo-extended-release 5/500 milligrams

Prescription medicationTabletOralExpired
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tabletDapagliflozin Propanediol Hydrate›6.15mg / 1 tablet
Manufacturer / importer
AstraZeneca Korea
Appearance
Orange, biconvex, rectangular film-coated tablet
Packaging
30 tablets (6 tablets x 5) / box
Approval status
Expired

MFDS item code 201503636 · Approved 2015.06.08

This product's status changed to Expired on 2024.11.26. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. For patients with no previous history of antidiabetic drug treatment and inadequate glycemic control with monotherapy: When used as initial therapy in patients with no previous history of antidiabetic drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the metformin dose currently being taken or an appropriately equivalent therapeutic dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjusted appropriately. For patients switching from concomitant dapagliflozin and metformin therapy to this medicine, the dose may be started at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because changes may result in altered glycemic control, any change in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dosage adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2, without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to be reduced in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Ingredients

Importer
AstraZeneca Korea

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This drug is used to improve blood sugar control in adult patients with type 2 diabetes, in combination with dapagliflozin and metformin, along with diet and exercise therapy. It may also be applicable in patients with cardiovascular disease or risk factors among those whose blood sugar is not well controlled; however, the effects of dapagliflozin on these patients should be referenced in professional information. This drug aids in blood sugar management and enhances the effectiveness of diabetes treatment.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. For patients with no previous history of antidiabetic drug treatment and inadequate glycemic control with monotherapy: When used as initial therapy in patients with no previous history of antidiabetic drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the metformin dose currently being taken or an appropriately equivalent therapeutic dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjusted appropriately. For patients switching from concomitant dapagliflozin and metformin therapy to this medicine, the dose may be started at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because changes may result in altered glycemic control, any change in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dosage adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2, without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to be reduced in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Precautions

This drug is used for diabetes treatment and helps control blood sugar. Although very rare, this drug can cause a serious metabolic complication known as lactic acidosis. Lactic acidosis is a condition in which the level of lactic acid in the blood rises and acidity increases, which can be life-threatening if not treated. Therefore, patients with poor kidney function or those with heart or liver issues should be especially cautious. Additionally, the risk of hypoglycemia may increase when this drug is used with insulin or sulfonylureas, so hypoglycemic symptoms should be closely monitored during co-administration. Patients with severely impaired kidney function, dehydration, acute infections, severe heart failure, or acute myocardial infarction should not use this drug, and it should be temporarily discontinued before and after tests using radiographic contrast agents. Patients with decreased fluid volume or low blood pressure, the elderly, and those on diuretics should be closely monitored for the risk of hypotension or deterioration of kidney function before and after administering this drug. This drug can cause genital and urinary tract infections, and if symptoms of infection appear, medical personnel should be notified immediately. There may be a deficiency in vitamin B12, so if taken for a long time, it is advisable to regularly check vitamin B12 levels in the blood. Women who are pregnant or may become pregnant, as well as breastfeeding women, should not use this drug, and use in children and those over 80 years old should be with caution. In case of overdose, appropriate treatment is necessary, and especially in patients with reduced kidney function, there is a risk of drug accumulation in the body, so caution is advised. Alcohol consumption should be avoided while taking this drug, and care should be taken to ensure that there are no symptoms of hypoglycemia or dehydration by monitoring meals and fluid intake. Finally, this drug should be stored out of reach of children, and kept in its original container to prevent misuse or degradation of quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvitis
  • balanitis
  • genitourinary infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 85 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar itching
  • genital itching
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • increased serum creatinine
  • increased blood urea
  • weight loss
  • ketosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal impairment
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignant neoplasm
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory abnormalities
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • myasthenia
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • itching
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly sealed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius. This helps to preserve the effectiveness and safety of the drug for a long time.

Appearance and packaging

Appearance

Orange, biconvex, rectangular film-coated tablet

Package unit

30 tablets (6 tablets x 5) / box

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.